Abstract A common concern in Bayesian data analysis is that an inappropriately informative prior may unduly influence posterior inferences. In the context of Bayesian clinical trial design, well chosen priors are important to ensure that posterior-based decision rules have good frequentist properties. However, it is difficult to quantify prior information in all but the most stylized models. This issue may be addressed by quantifying the prior information in terms of a number of hypothetical patients, i.e., a prior effective sample size (ESS). Prior ESS provides a useful tool for understanding the impact of prior assumptions. For example, the prior ESS may be used to guide calibration of prior variances and other hyperprior parameters. In this paper, we discuss such prior sensitivity analyses by using a recently proposed method to compute a prior ESS. We apply this in several typical settings of Bayesian biomedical data analysis and clinical trial design. The data analyses include cross-tabulated counts, multiple correlated diagnostic tests, and ordinal outcomes using a proportional-odds model.
Introduction
Understanding the strength of prior assumptions relative to the likelihood is a fundamental issue when applying Bayesian methods. The processes of formulating a putatively non-informative prior or eliciting a prior from an expert area typically require one to make many arbitrary choices, including the choice of particular distributional forms and numerical hyperparameter values. In practice, these choices are often dictated by technical convenience. A common criticism of Bayesian analysis is that an inappropriately informative prior may unduly influence posterior inferences and decisions. However, it is difficult to quantify and critique prior information in all but the most stylized models. These concerns may be addressed by quantifying the prior information in terms of an equivalent number of hypothetical patients, i.e., a prior effective sample size (ESS). Such a summary allows one to judge the relative contributions of the prior and the data to the final conclusions. A useful property of prior ESS is that it is readily interpretable by any scientifically literate reviewer without requiring expert mathematical training. This is important, for example, for consumers of clinical trial results.
The purpose of this paper is to discuss prior sensitivity analyses in Bayesian biostatistics by computing the prior ESS for six case studies chosen from the recent literature. We apply an ESS method proposed by Morita, Thall and Müller (MTM) [7] . Some of our case studies require prior ESS values for a subvector θ 1 of the parameter vector θ θ θ = (θ 1 , θ 2 ). The general definition allows the ESS to be specified for a subvector θ 1 of θ θ θ = (θ 1 , θ 2 ). However, ESS(θ 1 ) + ESS(θ 2 ) typically does not equal ESS(θ 1 , θ 2 ), because θ 1 in its marginal distribution often has a very different meaning than θ 1 in the joint distribution of (θ 1 , θ 2 ).
The case studies consist of three Bayesian data analyses and three study designs. The data analysis examples include small-sample cross-tabulated counts from an animal experiment to evaluate mechanical ventilator devices, bivariate normal modeling of paired data from multiple correlated diagnostic serologic tests, and proportionalodds modeling of ordinal outcomes arising from a study of viral effects in chick embryos. The study design examples include a phase I trial with dose-finding using the time-to-event continual reassessment method (TITE-CRM) [2] , a phase II trial with a stopping rule for monitoring event times, and a phase I/II clinical trial in which doses were assigned based on both efficacy and toxicity.
Section 2 provides a motivating example. In Sect. 3, we briefly summarize MTM. We discuss prior sensitivity in the real examples of Bayesian data analyses and study designs in Sect. 4 . We close with a brief discussion in Sect. 5.
A Motivating Example
The following example illustrates how the prior ESS may be used as an index of prior informativeness in a Bayesian sensitivity analysis and as a tool for critiquing a Bayesian data analysis when interpreting or formally reviewing the analysis.
Carlin [1] analyzed small-sample contingency table data from an experiment carried out to examine the effects of mechanical ventilator devices on lung damage in rabbits. In the experiment, the lungs of newborn rabbits were altered to simulate lung defects seen in human infants with underdeveloped lungs due to premature birth. The aim was to learn about the joint effects of different frequency and amplitude settings of the ventilators on lung damage. Six groups of six to eight animals each were compared using a factorial design with three frequency values crossed with two amplitudes. For amplitude g (= 1, 2 for 20 and 60, respectively) and frequency h (= 1, 2, 3 for 5, 10, and 15 Hz, respectively), let Y g,h denote the number of animals with lung damage out of n g,h studied and let π g,h denote the probability of lung damage in a cell (g, h) . The data are shown in Table 1 . Each cell reports the empirical frequency Y g,h /n g,h . Carlin [1] assumed the following logistic regression model:
where
Note that α g and β h are main effects for amplitude and frequency, while γ h is the interaction effect at frequency h and amplitude g = 2. Hence, the model parameter is
Carlin [1] assumed independent normal priors for μ, {α g }, {β h }, and {γ h }:
(1) Since the numbers of animals studied were very small, Carlin [1] explored the effect of a range of non-informative prior distributions in the analysis.
We use prior ESS to investigate sensitivity of the inferences to hyperparameter values by considering ten alternative choices that cover a range of reasonably noninformative settings. The ten hyperparameter choices, labeled N1 to N10, are shown in Table 2 . We add the four priors, N1 to N4, which would have smaller ESS values than those considered by Carlin [1] for priors N5 to N10. We apply MTM's method to compute an overall ESS for p(θ θ θ |θ θ θ), and also ESS μ , ESS α , ESS β , and ESS γ for the marginal priors on the subvectors μ, α α α
The prior N10 withσ α =σ β =σ γ = 0.5 has ESS = 36.6, so that its impact is roughly equal to that of the data (sample size n = 38) on the posterior inference. Thus, based on its ESS, the prior N10 may be criticized as being overly informative. Moreover, this prior has ESS γ = 96.1, thus it assumes very high prior information for the interaction effects. Because the prior means of the interactions are 0, this prior has the effect of shrinking the posterior estimates of the interaction parameters excessively toward 0. This illustrates two important points. First, a seemingly reasonable choice of (σ α ,σ β ,σ γ ) may give an excessively informative prior. Second, it is important to evaluate not only the overall ESS, but also the ESS values of subvectors of θ θ θ of particular interest. Such ESS computations help readers to interpret the reported posterior results, such as the estimates between the frequency groups displayed in Carlin ( Fig. 5.1 ) [1] . We will revisit this example below in Sect. 4. 
Prior Effective Sample Size
We briefly summarize the definition of ESS proposed by MTM [7] . While the discussion following this section does not require these details, we include this brief review for completeness. Let f (Y | θ θ θ) be the sampling model for a random vector Y indexed by parameter vector θ θ θ = (θ 1 , . . . , θ d ). We use f (Y | θ θ θ) generically to denote either a probability density function (pdf) or a probability mass function (pmf). The ESS is defined for a given prior p(θ θ θ |θ θ θ) on θ θ θ, having hyperparametersθ θ θ, with respect to the sampling model f (Y | θ θ θ). The approach of MTM is constructive. First, an ε-information prior q 0 (θ θ θ |θ θ θ 0 ) is defined that is similar to p(θ θ θ |θ θ θ) but is very vague in a suitable sense. This constructive definition may be understood in terms of the simple example where p(θ θ θ |θ θ θ) is a beta distribution, Be(α,β), for which the ESS is commonly considered to beα +β. In this case, the ε-information prior q 0 (θ θ θ |θ θ θ 0 ) is specified as Be(α/c,β/c) using an arbitrarily large value c > 0, so that the ESS (α +β)/c = ε of q 0 is very small while the meanα/(α +β) is the same as that of p(θ θ θ |θ θ θ). If m =α +β observations are obtained withα successes andβ failures then, starting with the ε-information prior q 0 (θ θ θ |θ θ θ 0 ), the posterior would be Be(α +α/c,β +β/c), 
where D p,j and D q,j are the curvatures of the original prior and the posterior under the ε-information prior,
. If interest is focused on a subvector θ θ θ r of θ θ θ , the ESS can be determined similarly in terms of the marginal prior p(θ θ θ r |θ θ θ). When the expectation cannot be obtained analytically, a simulation-based numerical approximation is used. For regression models of Y m as a function of a predictor X m , the likelihood is
In such settings, MTM augment the model by assuming a sampling model g m (X m | ξ ξ ξ) and prior r(ξ ξ ξ |ξ ξ ξ), and define
Case Studies of Data Analysis and Study Design
The following examples show how prior sensitivity may be evaluated using ESS in data analysis and clinical trial design settings. The first three, Examples 1 to 3, are data analyses and the latter three, Examples 4 to 6, are clinical trial designs. In each example, we explain how the prior ESS can be used as a tool to calibrate prior hyperparameters. Following Gelman et al. [6] , we write Unif(α, β),
, and MVN(μ, Σ), for the uniform, beta, binomial, gamma, exponential, normal, and multivariate normal distributions.
Cross-tabulated Counts from Small Samples-Example 1
This example was described earlier, in Sect. 2. The goal of Carlin's analysis was to examine the effects of mechanical ventilator devices on lung damage in rabbits. Because of the very small numbers of studied animals, as shown in Table 1 , the effect of a range of non-informative priors was explored. Recall that π g,h was the probability of lung damage in cell (g, h) for amplitude g (= 1, 2) and frequency h (= 1, 2, 3), and π g,h (θ θ θ) = logit
), where the model parameter
Using MTM's method, we compute an overall ESS, and also ESS μ , ESS α , ESS β , and ESS γ of the subvectors, which characterize the overall mean, the main effects for amplitude and frequency, and their interaction effects, respectively. The ESS values obtained for the ten alternative choices for the independent normal priors are summarized in Table 2 . As discussed in Sect. 2, since the sample size is 38, the prior N10 having the ESS = 36.6 may be criticized as being excessively informative. The priors N7 and N10 both assume very high prior information for the interaction effects. Both priors have ESS γ = 96.1. In this example, the ESS γ computation shows that the valueσ γ = 0.5 is far too small. While each of the hyperparametersσ α ,σ β ,σ γ can have an important impact on posterior inferences, they may be difficult to elicit or calibrate. We demonstrate here how one can use prior ESS graphically to assist in choosing these parameters. The idea is to compute the ESS for different combinations of the hyperparametersθ θ θ , similarly to Table 2. The ESS values are then plotted as a function ofθ θ θ . A practical problem is that one must first reduce the dimension ofθ θ θ to d = 2 to allow one to construct a contour plot of ESS as a function of two hyperparameter values. As a general strategy, we suggest the use of simple restrictions on elements ofθ θ θ . In this example, we will useσ α =σ β ≡σ , allowing us to plot ESS contours as a function of the two remaining hyperparameters (σ ,σ γ ). Figure 1 shows the contours for ESS = 0.1, 0.2, 0.5, 1.0, 2.0 and 5.0. From Fig. 1 one might, for example, decide to set σ α =σ β = 2.6 andσ γ = 4.7 to obtain ESS = 1.0.
Bivariate Normal Model for Multiple Correlated Diagnostic Tests-Example 2
Choi et al. [3] used a bivariate normal model to analyze multiple correlated diagnostic tests. They considered the problem of comparing two serologic tests, both enzymelinked immunosorbent assays (ELISA) for detection of antibodies to Johne's disease in dairy cattle. Data from n 1 = 88 diseased animals and n 0 = 393 disease-free animals were reported. The two tests have continuous outcomes, which we denote by Y 1iD and Y 2iD for the ith diseased animal, and by Y 1i D and Y 2i D for the i th diseasefree animal. Provided that the same prior and likelihood pair are used for the two independent data sets, they will have the same ESS value. Therefore, hereafter we will 2 ) and correlation ρ. Choi et al. [3] assume
so that θ θ θ = (μ 1 , μ 2 , τ 1 , τ 2 , ρ) and d = 5. To complete the model, Choi et al. [3] assume independent prior distributions
withμ j = 0,τ j = 0.001,ã j =b j = 0.001, j = 1, 2, and ρ ∼ Unif(−1, 1). The intention is to formalize vague prior information. In anticipation of the upcoming discussion, we use instead a more general scaled Beta prior, ρ ∼ rBe(α,β). The scaled To show how ESS may be applied as a tool for prior elicitation in this setting, we consider the four alternative priors shown in Table 3 . This serves as an informal sensitivity analysis. Also, similarly to the discussion in Sect. 4.1, we plot ESS as a function of the hyperparameters. We compute the ESS forτ 1 =τ 2 andã 1 =ã 2 = b 1 =b 2 each ranging from 0.001 to 10, keepingα =β = 1 fixed. Figure 2 gives plots of the resulting ESS values. For example, the prior ESS forτ 1 =τ 2 = 10,ã 1 = a 2 =b 1 =b 2 = 10,α =β = 1 is 9.5. This may be criticized as unacceptably high, considering the sample size of n = 88 diseased animals. In contrast, priors with all hyperparameters less than 1 correspond to reasonably small prior ESS. Table 4 . The data report deformity or mortality in chick embryos as a result of arbovirus injection. Two virus groups, Facey's Paddock (g = 1) and Tinaroo (g = 2), and a control group (g = 0) were investigated. The control group received no virus. The two virus groups and the control group contained n 1 = 75, n 2 = 72, and n 0 = 18 embryos, respectively. Each embryo in the Facey's Paddock group received one of the four doses, {3, 18, 30, 90}, denoted by In this example, a nonzero probability of death was assumed for zero dose. This accounts for a possible background mortality effect. In fact, one death was observed among the controls. The response in the control group Y 0,i is assumed to be binary (0 or 2) rather than trinary, with Pr(Y 0,i = 2 | α) = α, and Pr(Y g,i = h) is assumed to be a mixture 
Congdon [4] assumes independent prior distributions:
withφ = 1,μ β = 0 andσ 2 β = 10,μ κ = 0 andσ 2 κ = 100. We evaluate the overall ESS for θ θ θ , and subvector-specific ESS values ESS BG for θ 1 , and ESS DR for θ θ θ 2 . The computations yield ESS = 3.3, ESS BG = 3.6, and ESS DR = 0.85. Compared to the sample size of n = 165, the prior distributions used in this example appear appropriately non-informative. Figure 3 shows an ESS DR surface computed forσ 2 β andσ 2 κ ranging from 5 to 100, fixingφ = 1. The ESS surface suggests thatσ 2 β andσ 2 κ both over 50 provide a dose-response model with sufficiently vague priors. 
Time-to-Event Continual Reassessment Method-Example 4
The continual reassessment method (CRM) [9] is used for dose-finding in phase I clinical trials based on a binary indicator of toxicity. The CRM requires complete follow-up of the current patient (or cohort) before enrolling a new patient or cohort. Depending on how long it takes to evaluate toxicity, this may lead to an unduly long study duration that make the method impractical. Cheung and Chappell [2] proposed an extension, the time-to-event (TITE) CRM, that uses time to toxicity or right censoring as the outcome. Elkind et al. [5] applied the TITE-CRM to determine the maximum tolerated dose (MTD) of short-term high-dose lovastatin in stroke patients treated within 24 hours of symptom onset. Each patient received one of five initial doses 1, 3, 6, 8, 10 mg/kg, on days 1-3 post onset and received 20 mg/day for the next 27 days. Toxicity was assessed up to day 30, that is, the observation window was T up = 30 days. Denote the time-to-toxicity in patient i by u i , and the toxicity indicator Y i = 1 if u i ≤ T up , 0 if not, so that u i is right-censored at T up . The dose-toxicity model
was assumed, where d [i] is the standardized dose level assigned to patient i. An N(0, 1.34) distribution was assumed for the prior of β. The five standardized doses d = (d 1 , d 2 , d 3 , d 4 , d 5 ) in the model were assumed to be (0.02, 0.06, 0.10, 0.18, 0.30). In general, the TITE-CRM is implemented using the weighted working likelihood for m patients given by where w i is a suitable weight function. For the lovastatin trial, w i = u i /T up was used, and patients were assumed to arrive according to a Poisson process. This is equivalent to assuming that the inter-arrival times are i.i.d. Exp(λ). In the trial, λ = 2 patients per month was assumed.
In Table 5 , we assume five dose-toxicity scenarios in order to assess effects of the prior ESS. Scenario (1) corresponds to toxicity probabilities equal to the standardized doses. Scenarios (2)- (5) were constructed by starting with Scenario (1) and increasing the toxicity probabilities. In Scenarios (2) and (3), the toxicity probabilities increase linearly with dose, with all doses too toxic in Scenario (3). In Scenario (4), only d 1 is safe, with toxicity increasing rapidly from d 2 onward. In Scenario (5), all doses are very toxic.
As Cheung and Chappell [2] do, we assume three models for the patients' times to toxicity, including a conditionally uniform model, a Weibull model (with a fixed shape parameter 4), and a log-logistic model (with a fixed shape parameter 1). The cumulative distribution function (CDF) of the Weibull model with a scale parameter α is F (u, α) = 1 − exp{−(u/α) 4 } and the CDF of the log-logistic model with a scale parameter α is F (u, α)
We compute the ESS values under each model. Figure 4 gives plots of the ESS values as a function ofσ 2 under the five toxicity scenarios, assuming the conditionally uniform model for time-to-toxicity and with the prior mean of β fixed atμ = 0. Since the ESS computed atσ 2 = 1.34 is less than 2 under Scenario (1), the information from the likelihood will dominate the prior after enrolling 3 patients, hence the prior specified in the lovastatin trial seems quite reasonable. The prior also makes sense under Scenarios (2) and (3). The plot of ESS under Scenarios (4) and (5) indicates that the prior may be problematic, however. Under Scenario (5), it appears thatσ 2 > 2.5 may be needed to ensure an ESS < 2. The findings are similar under the Weibull and log-logistic models. This example illustrates that prior ESS computations can be a useful device to help calibrate the prior to improve the behavior of the TITE-CRM.
Trial Monitoring for Time-to-Event Outcomes-Example 5
Thall et al. [11] present a series of study designs for monitoring time-to-event outcomes in early phase clinical trials. We focus on one of the study designs, which was applied to a single-arm phase II trial for advanced kidney cancer. In the trial, the plan was to enroll up to 84 patients, with each patient's disease status evaluated up to 12 months. In this example, we focus on the mean time-to-event, μ. For patient i, let T i Fig. 4 Plots of ESS values againstσ 2 under the five toxicity scenarios given in Table 5 , in Example 4 (Cheung and Chappell [2] ). The vertical line atσ 2 = 1.34 indicates the hyperparameter value that was actually used in the lovastatin trial denote the time to disease progression (failure), let T o i be the observed value of T i or the administrative right-censoring time, and let Y i = I (T o i = T i ). We assume the t i 's are i.i.d. Exp(μ), exponential with mean μ, which has pdf f (t | μ) = μ −1 exp(−t/μ) and survivor function
Using the relationship μ = mean(T ) = median(T )/ log(2), Thall et al. [11] established the prior of μ S corresponding to the historical standard treatment from elicited mean values and a 95% credible interval of median(T ). This gave an inverse gamma IG(α,β) with (α,β) = (53.477, 301.61) as the prior p(μ S |μ μ μ S ). Here, IG(α,β) denotes an inverse gamma distribution with meanβ/(α − 1) and variancẽ β 2 /{(α − 1) 2 (α − 2)}, which requiresα > 2. The prior of μ E in the experimental treatment p(μ E |μ μ μ E ) was calibrated to have the same mean but inflated variance to reflect much greater prior uncertainty about the experimental treatment. This yielded μ E ∼ IG(5.348, 30.161). The time scale of the event time and its corresponding parameter μ are in months.
The prior ESS in a simple inverse gamma-exponential model with an inverse gamma prior, μ ∼ IG(α,β), and the exponential sampling model, T ∼ Exp(μ), is analytically determined to beα − 2. Thus, the ESS of the IG(5.348, 30.161) prior is 3.348 under this model. This prior ESS is obtained under the assumption that T is observed for all accrued patients; that is, no censoring occurs. Since in general the ESS is defined as a property of a prior and likelihood pair, a given prior might have different ESS values for different likelihoods. As mentioned in Sect. 3, our approach defines the ESS to be the sample size that yields a posterior containing the same amount of information as the prior. It is well known that the amount of information for time-to-event data depends on the number of observed events, not the sample size. Therefore, when T i is right-censored for some patients, the prior ESS should be larger thanα − 2. We apply MTM's method to compute an ESS under the inverse gamma prior μ E ∼ IG(5.348, 30.161) with respect to the likelihood (8) . The computation yields ESS = 4.8.
In clinical trials with Bayesian adaptive decision making, it is important to evaluate the impact of the prior on the stopping rule. In the study design of Thall et al. [11] , the trial should be stopped early if, based on the current data,
This rule stops the trial if it is unlikely that the mean failure time with the experimental treatment is at least a 4.3 month improvement over the historical mean with the standard treatment. The 4.3 month improvement in mean failure time corresponds to a 3.0 month improvement in median failure time, since 4.3 = 3.0/ log(2). In order to evaluate the impact of the prior of p(μ E |μ μ μ E ) on the stopping rule, we simulated the trial under each of a set of priors having different variances, corresponding to prior ESS values ranging from 1 to 20. We generated exponential patient event times using fixed (true) parameters μ true E = 5.7, 7.2, 8.6, 10.0, which correspond to median failure times of 4, 5, 6, 7 months. Each case was simulated 2000 times.
Figures 5a, 5b, and 5c illustrate the simulation results in terms of the probability of early termination (PET), the number of patients, and trial duration, respectively. 
The joint probabilities π a,b are modeled in terms of these marginal probabilities and one real-valued association parameter ψ : 
The prior p(θ θ θ |θ θ θ) was established from elicited mean values of π E (X,θ θ θ) and π T (X,θ θ θ), which yielded normal distributions with hyperparameters (μ μ E ,σ 2 ESS values computed for the subvectors of the parameters, as well as the full parameter vector, are a useful feedback in the prior elicitation process. We assume fixed hyperparametersμ μ E ,μ β E,1 ,μ β E,2 ,μ μ T ,μ β T , andμ ψ , and discuss the choice of the variance parametersσ μ E ,σ β E1 ,σ β E2 ,σ μ T ,σ β T , andσ ψ . We demonstrate how to calibrate the priors in this example. In the design described by Thall and Cook [10] , up to N = 36 patients are treated in cohorts of size = 3. Therefore, it may be desirable that the overall ESS and the subvector ESSs are at most 2, so that the accumulating data dominates the posterior inferences after enrolling 3 patients. Figure 6 shows Fig. 6c . One may choose, for example, σ ψ = 5.70, which provides ESS ψ = 2.0. The overall ESS value for the hyperparameter values chosen above is 2.0. If desired, one may repeat the procedure, starting with the choice of (σ μ E ,σ β E ), until a satisfactory overall ESS is obtained. In a last step one may drop the constraint onσ β E1 =σ β E2 and allow different values for these two parameters.
Discussion
We have discussed prior sensitivity analyses in Bayesian biostatistics by using prior ESS, illustrated by examples of data analysis and study design for biomedical studies. The main advantage of using ESS is practical feasibility. The definition is pragmatic and allows one to report a meaningful prior ESS summary for most problems. Another important feature is ease of communication. A user need not understand the mathematical underpinnings of the approach to interpret the final report, since the ESS is a hypothetical sample size, in terms of patients (or animals or experimental units), which is readily interpretable.
The ESS provides a numerical value for the effective sample size of a given prior. If one wishes to utilize this methodology to construct a prior having a given ESS, two important cases may be identified. When designing a small to moderate sized clinical trial using Bayesian methods, it is desirable that the prior ESS be small enough so that early decisions are dominated by the data (e.g. the first cohort of 3 patients in a dose-finding study) rather than the prior. In this case, an ESS in the range 0.5 to 2.0 may be appropriate. On the other hand, if one is eliciting a prior for analysis of a given data set of n observations, then a desirable ESS may be specified relative to n. In this case, an ESS of 0.10 ×n or smaller might be appropriate.
Morita, Thall, and Müller (MTM2) [8] develop a variation of the ESS suitable for conditionally independent hierarchical models (CIHMs). For a two-level CIHM with K subgroups, in the first level, Y k follows distribution f (Y k | θ θ θ k ), the subgroupspecific parameters θ θ θ = (θ θ θ 1 , . . . ,θ θ θ K ) are i.i.d. with prior π 1 (θ θ θ k |θ θ θ), and the hyperparameterθ θ θ has a hyperprior π 2 (θ θ θ | φ φ φ) with known φ φ φ. MTM2 define ESS under a CIHM in two cases, focusing on either the first level prior or second level prior, in order to address different inferential objectives. In case 1, the target is the marginalized prior, π 12 (θ θ θ | φ φ φ) = π 1 (θ θ θ |θ θ θ)π 2 (θ θ θ | φ φ φ) dθ θ θ , which may be of interest, for example, if θ θ θ 1 , . . . ,θ θ θ K are the treatment effects in K different canine breeds in a dietary study. In case 2, the target prior is π 2 (θ θ θ | φ φ φ), which would be the focus if the parameter of primary interest is an overall effectθ θ θ for canines, obtained by averaging over the K breeds.
Some important limitations remain. The methodology is based on comparing curvatures of the marginal prior and the posterior distribution under an ε-information prior. Consequently, when an analytic solution does not exist, a limitation is computational complexity. While the actual computational effort is negligible, the choice of a suitable ε-information prior and the evaluation of the prior-posterior distance require some problem-specific input from the investigator. That is, it is difficult to completely automate the ESS evaluation. However, the examples given here are intended to provide a basis for interested readers to compute and utilize prior ESS in similar problems. A computer program, ESS_RegressionCalculator.R, to calculate the ESS for a normal linear or logistic regression model is available from the website http://biostatistics.mdanderson.org/SoftwareDownload.
